Biogen Idec hires senior vice president
pharmafile | October 2, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Biogen IDEC, gene, olivier danos
US-based biotech firm Biogen Idec has hired Dr Olivier Danos to be the senior vice president of its gene therapy unit.
Danos will report to the firm’s R&D executive VP Dr Douglas Williams, and be a member of its senior research and development leadership team.
He will lead the company’s gene therapy research group in identifying and developing new technologies for gene transfer and genome engineering. Danos will also identify potential collaborations and support the development of treatments across the firm’s therapeutic focus areas.
“Olivier is a true pioneer in the field. We believe that his expertise will help accelerate our development of a world-class gene therapy platform that combines our growing internal capabilities with collaborations with leading research organisations across the globe,” says Williams.
“I have dedicated my career to advancing the use of gene therapy as a technology to develop life-saving therapies for patients,” adds Danos. “The team at Biogen Idec shares this passion. It is their commitment to innovative science and willingness to tackle difficult medical challenges that attracted me to the company. I am excited about the opportunities before us.”
Danos joins Biogen Idec from Kadmon Pharmaceuticals where since 2011 he served as senior VP, Molecular Medicine, Synthetic Biology and Gene Regulation. Prior to Kadmon, he acted as the director of the Gene Therapy Consortium of the University College of London and led a gene therapy research team at the Necker Hospital – Enfants Malades in Paris.
Related Content
Eplontersen recommended for EU approval by CHMP for treatment of hereditary transthyretin-mediated amyloidosis
Wainzua (eplotersen), produced by AstraZeneca and Ionis, has been recommended for approval in the European …
Blood biomarker discovered that can predict COVID-19 infection
Researchers have identified a gene, IFI27, that becomes activated in early stages of COVID-19 even …
Biogen to build billion-dollar plant in Switzerland
Biogen plans to open a $1 billion manufacturing facility in Switzerland, to help Europe deal …
